Josh Drumm, Ph.D., Author at CorMedix | Prevention of cardiac, renal and infectious diseases

CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases

Written by Josh Drumm, Ph.D. on December 5, 2017

Berkeley Heights, NJ – December 5, 2017 – CorMedix Inc….

CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology

Written by Josh Drumm, Ph.D. on November 29, 2017

Berkeley Heights, NJ – November 29, 2017 – CorMedix Inc….

CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team

Written by Josh Drumm, Ph.D. on November 20, 2017

Berkeley Heights, NJ – November 20, 2017 – CorMedix Inc….

CorMedix Inc. to Report Third Quarter 2017 Financial Results and Provide Business Update

Written by Josh Drumm, Ph.D. on November 7, 2017

Conference Call and Webcast to be held Wednesday, November 9,…

CorMedix Inc. to Present at The MicroCap Conference

Written by Josh Drumm, Ph.D. on September 28, 2017

Bedminster, NJ – September 28, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Relocates Corporate Headquarters

Written by Josh Drumm, Ph.D. on September 25, 2017

Berkeley Heights, NJ – September 25, 2017 – CorMedix Inc….

CorMedix Inc. to Present at the Anti-Infectives Rx Conference

Written by Josh Drumm, Ph.D. on September 12, 2017

Bedminster, NJ – September 12, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris

Written by Josh Drumm, Ph.D. on September 7, 2017

Poster Presented at the ASM/ESCMID Conference on Drug Development to…

CorMedix Inc. to Present at 2017 Rodman & Renshaw 19th Annual Global Investment Conference

Written by Josh Drumm, Ph.D. on September 5, 2017

Bedminster, NJ – September 5, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Announces a Change to its Senior Leadership

Written by Josh Drumm, Ph.D. on August 25, 2017

Bedminster, NJ – August 25, 2017 – CorMedix Inc. (NYSE…

CorMedix, Inc. Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and Prevention of Potentially Life-Threatening Infections in Severe Burns

Written by Josh Drumm, Ph.D. on August 17, 2017

Bedminster, NJ – August 17, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

Written by Josh Drumm, Ph.D. on August 9, 2017

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Directors

Written by Josh Drumm, Ph.D. on August 7, 2017

Current Director Myron Kaplan Elected Chairman of the Board Bedminster,…

CorMedix Inc. to Report Second Quarter 2017 Financial Results and Provide Business Update

Written by Josh Drumm, Ph.D. on August 4, 2017

Conference Call and Webcast to be held Wednesday, August 9,…

CorMedix Inc. Provides Update on Neutrolin® Ongoing Phase 3 Clinical Trial Following Favorable FDA Correspondence

Written by Josh Drumm, Ph.D. on August 2, 2017

Bedminster, NJ – August 2, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day

Written by Josh Drumm, Ph.D. on July 12, 2017

Live Webcast Today, July 12, 2017, beginning at 8:30am…

CorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day

Written by Josh Drumm, Ph.D. on June 14, 2017

Bedminster, NJ – June 14, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Announces Changes to Board of Directors

Written by Josh Drumm, Ph.D. on June 12, 2017

Bedminster, NJ – June 12, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update

Written by Josh Drumm, Ph.D. on May 10, 2017